Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

torrent pharma (uk) ltd - bicalutamide - oral tablet - 150mg

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - bicalutamide - oral tablet - 150mg

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

zydus lifesciences limited - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: hypersensitivity bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet's components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. women bicalutamide has no indication for women, and should not be used in this population. pregnancy bicalutamide can cause fetal harm when administered to a pregnant woman. [see use in specific populations (8.1) ]. risk summary bicalutamide is contraindicated for use in pregnant women because it can cause fetal harm. bicalutamide is not indicated for use in females. there are no human data on the use of bicalutam

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

relonchem ltd - bicalutamide - oral tablet - 150mg

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - bicalutamide - oral tablet - 150mg

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

major pharmaceuticals - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d 2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. bicalutamide has no indication for women, and should not be used in this population. bicalutamide can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)]. risk summary bicalutamide is contraindicated for use in pregnant women because it c

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - bicalutamide -

Բելգիա - անգլերեն - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - bicalutamide 50 mg - film-coated tablet - 50 mg - bicalutamide 50 mg - bicalutamide

Բելգիա - անգլերեն - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - bicalutamide 50 mg - film-coated tablet - 50 mg - bicalutamide 50 mg - bicalutamide

Բելգիա - անգլերեն - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - bicalutamide 50 mg - film-coated tablet - 50 mg - bicalutamide 50 mg - bicalutamide